To explore whether the activity increase occurs with other SUMF1 variants, we treated four different homozygous primary MSD patient fibroblast lines under standard conditions (10/20 μM tazarotene/bexarotene, 6 days). This evidence concerns the gene SUMF1 and Multiple sulfatase deficiency.